Paris Margaritis: Native Cellular Biology and the Future of Durable Hemophilia A Gene Therapy
Paris Margaritis, Chief Scientific Officer at GeneVentiv Therapeutics, Inc, shared on LinkedIn about a recent article by Paige E. Severeid et al, published in Blood Advances, adding:
”A newly published study in Blood Advances provides important insight into one of the key challenges facing current FVIII gene therapies for hemophilia A.
The paper further demonstrates that endogenous FVIII is produced primarily by liver sinusoidal endothelial cells (LSECs), not hepatocytes, and highlights that ‘discordance between natural FVIII biosynthesis sites and cellular targets of adeno-associated viral vectors has been implicated in efficacy limitations of current gene therapies for HA.’
The paper further reinforces the importance of aligning gene therapy design with endogenous cellular biology, an increasingly important consideration for durable expression in hemophilia gene therapy.
This is equally interesting and important work for the field and congratulations to all the authors and Roland W Herzog and Radoslaw (Radek) Kaczmarek.
Why this is important:
This work is highly relevant for hemophilia A gene therapies given the declining or variable expression observed with hepatocyte-targeted FVIII gene therapies such as valoctocogene roxaparvovec (Roctavian).
GeneVentiv’s GENV-HEM was designed to treat hemophilia A, regardless of inhibitors, from a fundamentally different biological premise.
Rather than forcing non-native FVIII expression in hepatocytes, GENV-HEM expresses activated human Factor V (FVa) in hepatocytes, the natural cellular site for Factor V synthesis.
This native-expression approach is intended to leverage the liver’s intrinsic biology, potentially supporting improved tolerability and long-term durability, including in patients with inhibitors.
Preclinical mouse data indeed support both such durability and efficacy and clinically relevant evaluation in hemophilia A dogs is currently ongoing.”
Title: Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells
Authors: Paige E. Severeid, Audrey Kapelanski-Lamoureux, Cynthia Lebeaupin, Peter Metrakos, Anthoula Lazaris, Wenjun Zhang, Chandrashekhar A. Kubal, Renzhi Han, Sreevani Arisa, Oded Danziger, Brad R. Rosenberg, Eleftherios Michailidis, Charles M. Rice, Ype P. de Jong, Randal J. Kaufman, Roland W. Herzog, Radoslaw Kaczmarek
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 29, 2026, 17:05What If Factor XI inhibition Could Reshape the Future of Anticoagulation – ISTH
-
Aug 29, 2026, 16:44Nipocalimab for Warm Autoimmune Hemolytic Anemia: What the FDA Approval Means
-
Aug 29, 2026, 16:17The Future of Bleeding Disorder Research is Getting Bigger – Global Hemophilia Report
-
Aug 29, 2026, 16:03Marco De Giovanni: The Platelet – Serotonin Link Behind Severe COVID-19
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:53Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community